Overview
- Description
Pharmaceutical company focused on the small molecule drug NTP42 for the treatment of pulmonary arterial hypertension (PAH).
- Website
- Project
- Country
- Ireland
- Theme
- Healthcare
ATXA Therapeutics Ltd
PAH-ADVANCE: Accelerating the Clinical Path of NTP42, a disease-modifying drug that will disrupt the future treatment of cardiopulmonary diseases, including pulmonary arterial hypertension (PAH).